{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:08:46Z","timestamp":1792782526505,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Milano - Bicocca","id":[{"id":"https:\/\/ror.org\/00wjc7c48","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This expert consensus aims to define how 2-deoxy-2-[18\u00a0F]-fluoro-D-glucose ([\u00b9\u2078F]FDG) positron emission tomography\/computed tomography (PET\/CT) can be systematically integrated into clinical pathways for early identification of diffuse large B-cell lymphoma (DLBCL) patients who may benefit from chimeric antigen receptor T-cell (CAR-T) therapy. The main research question is how PET-derived parameters and timing can optimize risk stratification and guide timely referral for advanced therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multidisciplinary panel of nuclear medicine physicians and hematologists conducted a structured consensus process based on current literature, international guidelines, and expert discussion. Key clinical scenarios and statements were evaluated across multiple meetings to assess the role of PET\/CT at baseline, interim, and end-of-treatment stages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PET\/CT provides critical prognostic information throughout the disease course. Baseline quantitative metrics (e.g., metabolic tumor volume) improve risk stratification beyond conventional indices. Interim PET, particularly using Deauville score and the change in the maximum standardized uptake value, enables early identification of high-risk or refractory patients. End-of-treatment PET remains essential for response assessment and therapeutic decision-making. Standardization of acquisition, reporting, and interpretation is necessary to enhance reproducibility and clinical integration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PET\/CT should be considered a central biomarker in DLBCL management, enabling earlier identification of high-risk patients and facilitating timely CAR-T referral. Harmonized, multidisciplinary implementation is essential to optimize outcomes and improve access to potentially curative therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-07999-9","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:52:25Z","timestamp":1782456745000},"page":"6800-6812","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4197-2060","authenticated-orcid":false,"given":"Luca","family":"Guerra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Albano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"Angelillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Di Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Farolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Visco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"7999_CR1","unstructured":"Padala SA, Kallam A, Diffuse Large B-C, Lymphoma. [Updated 2023 Apr 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557796\/"},{"issue":"1","key":"7999_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s12672-025-01958-w","volume":"16","author":"A Berhan","year":"2025","unstructured":"Berhan A, Almaw A, Damtie S, Solomon Y. Diffuse large B cell lymphoma (DLBCL): epidemiology, pathophysiology, risk stratification, advancement in diagnostic approaches and prospects: narrative review. Discov Oncol. 2025;16(1):184. https:\/\/doi.org\/10.1007\/s12672-025-01958-w","journal-title":"Discov Oncol"},{"issue":"9","key":"7999_CR3","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G, Diffuse Large B-C, Lymphoma. N Engl J Med. 2021;384(9):842\u201358. https:\/\/doi.org\/10.1056\/NEJMra2027612","journal-title":"N Engl J Med"},{"issue":"6","key":"7999_CR4","doi-asserted-by":"publisher","first-page":"366","DOI":"10.46883\/2022.25920963","volume":"36","author":"M Kesireddy","year":"2022","unstructured":"Kesireddy M, Lunning M. Relapsed or refractory diffuse large B-Cell lymphoma: Dazed and confused. Oncol (Williston Park). 2022;36(6):366\u201375. https:\/\/doi.org\/10.46883\/2022.25920963","journal-title":"Oncol (Williston Park)"},{"issue":"23","key":"7999_CR5","doi-asserted-by":"publisher","first-page":"7376","DOI":"10.3390\/jcm12237376","volume":"12","author":"E Gonzalez Barca","year":"2023","unstructured":"Gonzalez Barca E. Developing new strategies for relapsed\/refractory diffuse large B-Cell lymphoma. J Clin Med. 2023;12(23):7376. https:\/\/doi.org\/10.3390\/jcm12237376","journal-title":"J Clin Med"},{"key":"7999_CR6","doi-asserted-by":"publisher","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20131808. doi: 10.1182\/blood-2017-03-769620. Epub 2017 Aug 3. Erratum in: Blood. 2018;131(5):587\u2013588. https:\/\/doi.org\/10.1182\/blood-2017-11-817775. PMID: 28774879; PMCID: PMC5649550.","DOI":"10.1182\/blood-2017-11-817775"},{"issue":"11","key":"7999_CR7","first-page":"898","volume":"31","author":"MA Kharfan-Dabaja","year":"2025","unstructured":"Kharfan-Dabaja MA, Reljic T, Mohty R, Tawk M, Abdel-Razeq S, Keller K, Iqbal M, Moustafa MA, Aljurf M, Qin H, Kumar A. Treatment of diffuse large B-cell lymphoma progressing or relapsing after chimeric antigen receptor T-cell therapy. Transpl Cell Ther. 2025;31(11):898.e1-898.e12.","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"7999_CR8","doi-asserted-by":"publisher","first-page":"e70317","DOI":"10.1002\/cncr.70317","volume":"132","author":"L Tang","year":"2026","unstructured":"Tang L, Cai D, Yan X, Mo W. Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis. Cancer. 2026;132(4):e70317. https:\/\/doi.org\/10.1002\/cncr.70317","journal-title":"Cancer"},{"issue":"7","key":"7999_CR9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa2116596","volume":"386","author":"MR Bishop","year":"2022","unstructured":"Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022;386(7):629\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2116596.","journal-title":"N Engl J Med"},{"issue":"2","key":"7999_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389(2):148\u201357. https:\/\/doi.org\/10.1056\/NEJMoa2301665.","journal-title":"N Engl J Med"},{"issue":"24","key":"7999_CR11","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1200\/JCO-25-00399","volume":"43","author":"M Kamdar","year":"2025","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Chow VA, Montheard S, Santamaria J, Colicino S, Ogasawara K, Stepan L, Liu FF, Abramson JS. Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed\/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study. J Clin Oncol. 2025;43(24):2671\u20138. https:\/\/doi.org\/10.1200\/JCO-25-00399","journal-title":"J Clin Oncol"},{"issue":"14","key":"7999_CR12","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1080\/10428194.2025.2560082","volume":"66","author":"S Gupta","year":"2025","unstructured":"Gupta S, Bachanova V. CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma: lessons learned from clinical trials and real world evidence. Leuk Lymphoma. 2025;66(14):2588\u2013600. Epub 2025 Oct 10. PMID: 41070560.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"7999_CR13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s40644-024-00810-8","volume":"24","author":"Z Sun","year":"2024","unstructured":"Sun Z, Yang T, Ding C, Shi Y, Cheng L, Jia Q, Tao W. Clinical scoring systems, molecular subtypes and baseline [18F]FDG PET\/CT image analysis for prognosis of diffuse large B-cell lymphoma. Cancer Imaging. 2024;24(1):168. https:\/\/doi.org\/10.1186\/s40644-024-00810-8","journal-title":"Cancer Imaging"},{"issue":"11","key":"7999_CR14","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.jcyt.2025.07.007","volume":"27","author":"S Luminari","year":"2025","unstructured":"Luminari S, Chiappella A, Rocco AD, Arcaini L, Freilone R, Ladetto M, Martino M, Musto P, Rigacci L, Visco C, Corradini P, Zinzani PL. Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus. Cytotherapy. 2025;27(11):1316\u201325.","journal-title":"Cytotherapy"},{"issue":"7","key":"7999_CR15","first-page":"440","volume":"29","author":"MS Hoffmann","year":"2023","unstructured":"Hoffmann MS, Hunter BD, Cobb PW, Varela JC, Munoz J. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed\/Refractory Diffuse Large B Cell Lymphoma. Transpl Cell Ther. 2023;29(7):440\u20138.","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"7999_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-026-01458-2","volume":"16","author":"SM Ansell","year":"2026","unstructured":"Ansell SM, Nowakowski GS. Current treatment algorithm: diffuse large B cell lymphoma. Blood Cancer J. 2026;16(1):32. https:\/\/doi.org\/10.1038\/s41408-026-01458-2","journal-title":"Blood Cancer J"},{"issue":"5","key":"7999_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1159\/000346303","volume":"22","author":"EK Pauwels","year":"2013","unstructured":"Pauwels EK, Coumou AW, Kostkiewicz M, Kairemo K. [\u00b9\u2078F]fluoro-2-deoxy-d-glucose positron emission tomography\/computed tomography imaging in oncology: initial staging and evaluation of cancer therapy. Med Princ Pract. 2013;22(5):427\u201337.","journal-title":"Med Princ Pract"},{"issue":"12","key":"7999_CR18","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3390\/bioengineering11121213","volume":"11","author":"D Hussain","year":"2024","unstructured":"Hussain D, Abbas N, Khan J. Recent Breakthroughs in PET-CT Multimodality Imaging: Innovations and Clinical Impact. Bioeng (Basel). 2024;11(12):1213. https:\/\/doi.org\/10.3390\/bioengineering11121213","journal-title":"Bioeng (Basel)"},{"issue":"1","key":"7999_CR19","doi-asserted-by":"publisher","first-page":"e0210224","DOI":"10.1371\/journal.pone.0210224","volume":"14","author":"B Guo","year":"2019","unstructured":"Guo B, Tan X, Ke Q, Cen H. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis. PLoS ONE. 2019;14(1):e0210224. https:\/\/doi.org\/10.1371\/journal.pone.0210224","journal-title":"PLoS ONE"},{"issue":"7","key":"7999_CR20","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3324\/haematol.2021.278663","volume":"107","author":"L Kostakoglu","year":"2022","unstructured":"Kostakoglu L, Mattiello F, Martelli M, Sehn LH, Belada D, Ghiggi C, Chua N, Gonz\u00e1lez-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Bolen C, Knapp A, Sellam G, Nielsen T, Sahin D, Vitolo U, Trn\u011bn\u00fd M. Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study. Haematologica. 2022;107(7):1633\u201342. https:\/\/doi.org\/10.3324\/haematol.2021.278663","journal-title":"Haematologica"},{"issue":"16","key":"7999_CR21","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1182\/blood.2019003526","volume":"135","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Cottereau AS, Casasnovas O, Tilly H, Feugier P, Chartier L, Fruchart C, Roulin L, Oberic L, Pica GM, Ribrag V, Abraham J, Simon M, Gonzalez H, Bouabdallah R, Fitoussi O, Sebban C, L\u00f3pez-Guillermo A, Sanhes L, Morschhauser F, Trotman J, Corront B, Choufi B, Snauwaert S, Godmer P, Briere J, Salles G, Gaulard P, Meignan M, Thieblemont C. High total metabolic tumor volume at baseline predicts survival independent of response to therapy. Blood. 2020;135(16):1396\u2013405. https:\/\/doi.org\/10.1182\/blood.2019003526","journal-title":"Blood"},{"issue":"4","key":"7999_CR22","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2967\/jnumed.122.264740","volume":"64","author":"L Michaud","year":"2023","unstructured":"Michaud L, Bantilan K, Mauguen A, Moskowitz CH, Zelenetz AD, Sch\u00f6der H. Prognostic Value of 18F-FDG PET\/CT in Diffuse Large B-Cell Lymphoma Treated with a Risk-Adapted Immunochemotherapy Regimen. J Nucl Med. 2023;64(4):536\u201341. https:\/\/doi.org\/10.2967\/jnumed.122.264740","journal-title":"J Nucl Med"},{"issue":"25","key":"7999_CR23","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1182\/blood.2019003277","volume":"135","author":"H Sch\u00f6der","year":"2020","unstructured":"Sch\u00f6der H, Polley MC, Knopp MV, Hall N, Kostakoglu L, Zhang J, Higley HR, Kelloff G, Liu H, Zelenetz AD, Cheson BD, Wagner-Johnston N, Kahl BS, Friedberg JW, Hsi ED, Leonard JP, Schwartz LH, Wilson WH, Bartlett NL. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood. 2020;135(25):2224\u201334. https:\/\/doi.org\/10.1182\/blood.2019003277","journal-title":"Blood"},{"issue":"4","key":"7999_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/mnm.0000000000001664","volume":"44","author":"S Czibor","year":"2023","unstructured":"Czibor S, Carr R, Redondo F, Auewarakul CU, Cerci JJ, Paez D, Fanti S, Gy\u00f6rke T. Prognostic parameters on baseline and interim [ 18 F]FDG-PET\/computed tomography in diffuse large B-cell lymphoma patients. Nucl Med Commun. 2023;44(4):291\u2013301. https:\/\/doi.org\/10.1097\/mnm.0000000000001664","journal-title":"Nucl Med Commun"},{"issue":"10438","key":"7999_CR25","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","volume":"403","author":"E Silkenstedt","year":"2024","unstructured":"Silkenstedt E, Salles G, Campo E, Dreyling M. B-cell non-Hodgkin lymphomas. Lancet. 2024;403(10438):1791\u2013807. https:\/\/doi.org\/10.1016\/S0140-6736(23)02705-8","journal-title":"Lancet"},{"issue":"1","key":"7999_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-024-01540-x","volume":"17","author":"D Leithner","year":"2024","unstructured":"Leithner D, Flynn JR, Devlin SM, Mauguen A, Fei T, Zeng S, Zheng J, Imber BS, Hubbeling H, Mayerhoefer ME, Bedmutha A, Luttwak E, Corona M, Dahi PB, Luna de Abia A, Landego I, Lin RJ, Palomba ML, Scordo M, Park JH, Tomas AA, Salles G, Lafontaine D, Michaud L, Shah GL, Perales MA, Shouval R, Sch\u00f6der H. Conventional and novel [18F]FDG PET\/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma. J Hematol Oncol. 2024;17(1):21. https:\/\/doi.org\/10.1186\/s13045-024-01540-x","journal-title":"J Hematol Oncol"},{"issue":"8","key":"7999_CR27","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.2967\/jnumed.125.269670","volume":"66","author":"A Farolfi","year":"2025","unstructured":"Farolfi A, Casadei B, Malizia C, Ussia R, Rocchi V, Paccagnella A, Gentilini M, Nanni C, Argnani L, Zinzani PL, Fanti S. Semiquantitative PET Parameters Refine Prognosis in CAR T-Treated Lymphoma After 1 and 3 Months: A Prospective Single-Center Study. J Nucl Med. 2025;66(8):1183\u201391. https:\/\/doi.org\/10.2967\/jnumed.125.269670","journal-title":"J Nucl Med"},{"key":"7999_CR28","doi-asserted-by":"publisher","unstructured":"Ababneh HS, Ng AK, Abramson JS, Soumerai JD, Takvorian RW, Frigault MJ, Patel CG. Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed\/refractory large B-cell lymphoma. Hematol Oncol. 2024;42(1):e3231. https:\/\/doi.org\/10.1002\/hon.3231","DOI":"10.1002\/hon.3231"},{"issue":"2","key":"7999_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12149-022-01820-x","volume":"37","author":"G Akamatsu","year":"2023","unstructured":"Akamatsu G, Tsutsui Y, Daisaki H, Mitsumoto K, Baba S, Sasaki M. A review of harmonization strategies for quantitative PET. Ann Nucl Med. 2023;37(2):71\u201388. https:\/\/doi.org\/10.1007\/s12149-022-01820-x","journal-title":"Ann Nucl Med"},{"key":"7999_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.critrevonc.2019.05.010","volume":"141","author":"HJA Adams","year":"2019","unstructured":"Adams HJA, Kwee TC. Proportion of false-positive follow-up FDG-PET scans in lymphoma: Systematic review and meta-analysis. Crit Rev Oncol Hematol. 2019;141:73\u201381. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.05.010.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"7999_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40336-021-00445-w","volume":"9","author":"M Casali","year":"2021","unstructured":"Casali M, Lauri C, Altini C, Bertagna F, Cassarino G, Cistaro A, Erba AP, Ferrari C, Mainolfi CG, Palucci A, Prandini N, Baldari S, Bartoli F, Bartolomei M, D\u2019Antonio A, Dondi F, Gandolfo P, Giordano A, Laudicella R, Massollo M, Nieri A, Piccardo A, Vendramin L, Muratore F, Lavelli V, Albano D, Burroni L, Cuocolo A, Evangelista L, Lazzeri E, Quartuccio N, Rossi B, Rubini G, Sollini M, Versari A, Signore A. State of the art of 18F-FDG PET\/CT application in inflammation and infection: a guide for image acquisition and interpretation. Clin Transl Imaging. 2021;9(4):299\u2013339. https:\/\/doi.org\/10.1007\/s40336-021-00445-w","journal-title":"Clin Transl Imaging"},{"key":"7999_CR32","doi-asserted-by":"publisher","first-page":"153535082412579","DOI":"10.1177\/15353508241257924","volume":"23","author":"SB Singh","year":"2024","unstructured":"Singh SB, Bhandari S, Siwakoti S, Kumar M, Singh R, Bhusal S, Sharma K, Bhandari S, Khanal K. PET\/CT in the Evaluation of CAR-T Cell Immunotherapy in Hematological Malignancies. Mol Imaging. 2024;23:15353508241257924.","journal-title":"Mol Imaging"},{"issue":"5","key":"7999_CR33","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1007\/s00277-025-06368-0","volume":"104","author":"J Gao","year":"2025","unstructured":"Gao J, Liu S, Zhao M, Zhang H, Jing H. Prognostic role of interim PET-CT demonstrating partial metabolic response in diffuse large B-Cell lymphoma: a retrospective study. Ann Hematol. 2025;104(5):2777\u201386. https:\/\/doi.org\/10.1007\/s00277-025-06368-0","journal-title":"Ann Hematol"},{"key":"7999_CR34","doi-asserted-by":"publisher","first-page":"1128295","DOI":"10.3389\/fmed.2023.1128295","volume":"10","author":"M\u00c1 Canales Albendea","year":"2023","unstructured":"Canales Albendea M\u00c1, Canonico PL, Cartron G, Deiters B, Jommi C, Marks R, Rioufol C, Sancho Cia JM, Santoro A, Wagner-Drouet EM. Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries. Front Med (Lausanne). 2023;10:1128295. https:\/\/doi.org\/10.3389\/fmed.2023.1128295","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"7999_CR35","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.annonc.2025.07.014","volume":"36","author":"TA Eyre","year":"2025","unstructured":"Eyre TA, Cwynarski K, d\u2019Amore F, de Leval L, Dreyling M, Eichenauer DA, Ferreri AJM, Gin\u00e9 E, Kersten MJ, Ladetto M, Specht L, Thieblemont C, Walewski J, Zucca E, Jerkeman M, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36(11):1263\u201384.","journal-title":"Ann Oncol"},{"key":"7999_CR36","doi-asserted-by":"publisher","unstructured":"Thieblemont C, Gomes Da Silva M, Lepp\u00e4 S, Lenz G, Cottereau AS, Fox C, Lopez-Guillermo A, Illidge T, Jurczak W, Eich H, Aurer I, Trneny M, Rosenwald AA, Davies A, Zwezerijnen BG, Bolanos N, Markovi\u0107 M, Jais JP, Broussais F, Dreyling M, Vitolo U, Tilly H, Kersten MJ. Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Hemasphere. 2025;9(9):e70207. doi: 10.1002\/hem3.70207. Erratum in: Hemasphere. 2025;9(12):e70273. https:\/\/doi.org\/10.1002\/hem3.70273. PMID: 40995463; PMCID: PMC12456099.","DOI":"10.1002\/hem3.70273"},{"issue":"3","key":"7999_CR37","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2967\/jnumed.119.238923","volume":"62","author":"SF Barrington","year":"2021","unstructured":"Barrington SF, Zwezerijnen BGJC, de Vet HCW, Heymans MW, Mikhaeel NG, Burggraaff CN, Eertink JJ, Pike LC, Hoekstra OS, Zijlstra JM, Boellaard R. Automated segmentation of baseline metabolic total tumor burden in diffuse large B-Cell lymphoma: Which method is most successful? A study on behalf of the PETRA consortium. J Nucl Med. 2021;62(3):332\u20137.","journal-title":"J Nucl Med"},{"key":"7999_CR38","doi-asserted-by":"publisher","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, M\u00fceller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O\u2019Doherty MJ, Hustinx R, Biggi A, Cheson BD. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048-58. https:\/\/doi.org\/10.1200\/JCO.2013.53.5229. Erratum in: J Clin Oncol. 2016;34(21):2562. doi: 10.1200\/JCO.2016.68.9265. PMID: 25113771; PMCID: PMC5015423.","DOI":"10.1200\/JCO.2013.53.5229"},{"issue":"1","key":"7999_CR39","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1016\/S2352-3026(20)30365-3","volume":"8","author":"SF Barrington","year":"2021","unstructured":"Barrington SF, Trotman J. The Role of PET in the First-Line Treatment of the Most Common Subtypes of Non-Hodgkin Lymphoma. Lancet Haematol. 2021;8(1):e80\u201393. https:\/\/doi.org\/10.1016\/S2352-3026(20)30365-3.","journal-title":"Lancet Haematol"},{"issue":"3","key":"7999_CR40","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","volume":"32","author":"AS Cottereau","year":"2021","unstructured":"Cottereau AS, Meignan M, Nioche C, et al. Risk Stratification in Diffuse Large B-Cell Lymphoma Using Lesion Dissemination and Metabolic Tumor Burden Calculated From Baseline PET\/CT. Annals of Oncology. Official J Eur Soc Med Oncol. 2021;32(3):404\u201311. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.019.","journal-title":"Official J Eur Soc Med Oncol"},{"key":"7999_CR41","doi-asserted-by":"publisher","first-page":"1395824","DOI":"10.3389\/fonc.2024.1395824","volume":"14","author":"C Liao","year":"2024","unstructured":"Liao C, Deng Q, Zeng L, et al. Baseline and interim 18f-FDG PET\/CT metabolic parameters predict the efficacy and survival in patients with diffuse large B-Cell lymphoma. Front Oncol. 2024;14:1395824. https:\/\/doi.org\/10.3389\/fonc.2024.1395824","journal-title":"Front Oncol"},{"issue":"25","key":"7999_CR42","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1182\/blood.2022018558","volume":"141","author":"JJ Eertink","year":"2023","unstructured":"Eertink JJ, Zwezerijnen GJC, Heymans MW, et al. Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-Cell lymphoma. Blood. 2023;141(25):3055\u201364. https:\/\/doi.org\/10.1182\/blood.2022018558","journal-title":"Blood"},{"issue":"10","key":"7999_CR43","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1007\/s00259-021-05233-2","volume":"48","author":"R Frood","year":"2021","unstructured":"Frood R, Burton C, Tsoumpas C, et al. Baseline PET\/CT imaging parameters for prediction of treatment outcome in hodgkin and diffuse large B Cell lymphoma: A systematic review. Eur J Nucl Med Mol Imaging. 2021;48(10):3198\u2013220. https:\/\/doi.org\/10.1007\/s00259-021-05233-2","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"50","key":"7999_CR44","doi-asserted-by":"publisher","first-page":"83544","DOI":"10.18632\/oncotarget.13180","volume":"7","author":"M Zhou","year":"2016","unstructured":"Zhou M, Chen Y, Huang H, Zhou X, Liu J, Huang G. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in diffuse large B-cell lymphoma. Oncotarget. 2016;7(50):83544\u201353. https:\/\/doi.org\/10.18632\/oncotarget.13180 . PMID: 27835875; PMCID: PMC5347787.","journal-title":"Oncotarget"},{"key":"7999_CR45","doi-asserted-by":"publisher","first-page":"1726567","DOI":"10.3389\/fmed.2025.1726567","volume":"12","author":"S Tasevski","year":"2026","unstructured":"Tasevski S, Treglia G, Marin A, Bertagna F, Albano D. The prognostic role of maximum tumor dissemination derived by PET\/CT in oncological diseases: a systematic review. Front Med (Lausanne). 2026;12:1726567. https:\/\/doi.org\/10.3389\/fmed.2025.1726567 . PMID: 41561936; PMCID: PMC12812955.","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"7999_CR46","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2967\/jnumed.124.267789","volume":"65","author":"R Boellaard","year":"2024","unstructured":"Boellaard R, Buvat I, Nioche C, Ceriani L, Cottereau AS, Guerra L, Hicks RJ, Kanoun S, Kobe C, Loft A, Sch\u00f6der H, Versari A, Voltin CA, Zwezerijnen GJC, Zijlstra JM, Mikhaeel NG, Gallamini A, El-Galaly TC, Hanoun C, Chauvie S, Ricci R, Zucca E, Meignan M, Barrington SF. International benchmark for total metabolic tumor volume measurement in baseline 18F-FDG PET\/CT of lymphoma patients: A milestone toward clinical implementation. J Nucl Med. 2024;65(9):1343\u20138. https:\/\/doi.org\/10.2967\/jnumed.124.267789","journal-title":"J Nucl Med"},{"issue":"2","key":"7999_CR47","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2025","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ. European Association of Nuclear Medicine (EANM). FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2025;42(2):328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"7999_CR48","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.2967\/jnumed.119.227249","volume":"60","author":"SF Barrington","year":"2019","unstructured":"Barrington SF, Meignan M. Time to Prepare for Risk Adaptation in Lymphoma by Standardizing Measurement of Metabolic Tumor Burden. J Nucl Med. 2019;60(8):1096\u2013102. https:\/\/doi.org\/10.2967\/jnumed.119.227249.","journal-title":"J Nucl Med"},{"issue":"7","key":"7999_CR49","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1007\/s00259-018-3953-z","volume":"45","author":"H Ilyas","year":"2018","unstructured":"Ilyas H, Mikhaeel NG, Dunn JT, Rahman F, M\u00f8ller H, Smith D, Barrington SF. Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45(7):1142\u201354. https:\/\/doi.org\/10.1007\/s00259-018-3953-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7999_CR50","unstructured":"Wang J, Zhao J. Clinical practice guideline of PET\/CT and PET\/MR in lymphoma (2025 edition). https:\/\/mednexus.org\/doi\/full\/10.65457\/JNMMI-2026-0023. Accessed 29 April 2026."},{"issue":"4","key":"7999_CR51","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1007\/s00330-023-10150-z","volume":"34","author":"A El-Azony","year":"2024","unstructured":"El-Azony A, Basha MAA, Almalki YE, et al. The Prognostic Value of Bone Marrow Retention Index and Bone Marrow-to-Liver Ratio of Baseline 18f-Fdg pet\/Ct in Diffuse Large B-Cell Lymphoma. Eur Radiol. 2024;34(4):2500\u201311. https:\/\/doi.org\/10.1007\/s00330-023-10150-z.","journal-title":"Eur Radiol"},{"issue":"7","key":"7999_CR52","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41568-023-00576-4","volume":"23","author":"J Schwenck","year":"2023","unstructured":"Schwenck J, Sonanini D, Cotton JM, Rammensee HG, la Foug\u00e8re C, Zender L, Pichler BJ. Advances in PET imaging of cancer. Nat Rev Cancer. 2023;23(7):474\u201390. https:\/\/doi.org\/10.1038\/s41568-023-00576-4","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"7999_CR53","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1200\/JCO.21.02063","volume":"40","author":"NG Mikhaeel","year":"2022","unstructured":"Mikhaeel NG, Heymans MW, Eertink JJ, de Vet HCW, Boellaard R, D\u00fchrsen U, Ceriani L, Schmitz C, Wiegers SE, H\u00fcttmann A, Lugtenburg PJ, Zucca E, Zwezerijnen GJC, Hoekstra OS, Zijlstra JM, Barrington SF. Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index. J Clin Oncol. 2022;40(21):2352\u201360.","journal-title":"J Clin Oncol"},{"issue":"7","key":"7999_CR54","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00259-019-04309-4","volume":"46","author":"QA Shagera","year":"2019","unstructured":"Shagera QA, Cheon GJ, Koh Y, Yoo MY, Kang KW, Lee DS, Kim EE, Yoon SS, Chung JK. Prognostic value of metabolic tumour volume on baseline 18F-FDG PET\/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI. Eur J Nucl Med Mol Imaging. 2019;46(7):1417\u201327. https:\/\/doi.org\/10.1007\/s00259-019-04309-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7999_CR55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12149-020-01531-1","volume":"35","author":"P Zhao","year":"2021","unstructured":"Zhao P, Yu T, Pan Z. Prognostic value of the baseline 18F-FDG PET\/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL. Ann Nucl Med. 2021;35(1):24\u201330. https:\/\/doi.org\/10.1007\/s12149-020-01531-1","journal-title":"Ann Nucl Med"},{"key":"7999_CR56","doi-asserted-by":"publisher","unstructured":"Voltin CA, Flossdorf S, Kurch L, Winkelmann M, Farolfi A, Beckmann L, Casadei B, Herrmann K, Kutsch N, Borchmann P, Brendel M, Blumenberg V, Fanti S, Zinzani PL, Rahbar K, Sheikh GT, Sabri O, Drzezga A, Dietlein M, Reinhardt HC, Kunz WG, Albring JC, Seifert R, von Tresckow B, Heger JM, G\u00f6del P, Subklewe M, Paccagnella A, Vu\u010dini\u0107 V, Hanoun C. Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy. J Nucl Med. 2026 Mar 19:jnumed.125.271976. https:\/\/doi.org\/10.2967\/jnumed.125.271976. Epub ahead of print. PMID: 41856668.","DOI":"10.2967\/jnumed.125.271976"},{"issue":"10","key":"7999_CR57","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.1007\/s00277-025-06686-3","volume":"104","author":"A Duminuco","year":"2025","unstructured":"Duminuco A, Scarso S, Del Fabro V, Caruso LA, Stanzione G, Di Raimondo F, Palumbo GA, Vetro C. Diffuse large B-cell lymphoma in the new era: prognostic tools for mapping risk. Ann Hematol. 2025;104(10):4897\u2013911. https:\/\/doi.org\/10.1007\/s00277-025-06686-3","journal-title":"Ann Hematol"},{"key":"7999_CR58","unstructured":"NCCN Guidelines for B-Cell Lymphomas. https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/10\/article-e250048.xml. Accessed 7 April 2026."},{"issue":"9","key":"7999_CR59","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/bloodadvances.2021004467","volume":"5","author":"JJ Eertink","year":"2021","unstructured":"Eertink JJ, Burggraaff CN, Heymans MW, D\u00fchrsen U, H\u00fcttmann A, Schmitz C, M\u00fcller S, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Carr R, Czibor S, Gy\u00f6rke T, Ceriani L, Zucca E, Hutchings M, Kostakoglu L, Loft A, Fanti S, Wiegers SE, Pieplenbosch S, Boellaard R, Hoekstra OS, Zijlstra JM, de Vet HCW. Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. Blood Adv. 2021;5(9):2375\u201384. https:\/\/doi.org\/10.1182\/bloodadvances.2021004467","journal-title":"Blood Adv"},{"issue":"11","key":"7999_CR60","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.2967\/jnumed.123.265871","volume":"64","author":"E Itti","year":"2023","unstructured":"Itti E, Blanc-Durand P, Berriolo-Riedinger A, Kanoun S, Kraeber-Bod\u00e9r\u00e9 F, Meignan M, Gat E, Gouill SL, Casasnovas RO, Bodet-Milin C. Validation of the \u2206SUVmax for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial. J Nucl Med. 2023;64(11):1706\u201311. https:\/\/doi.org\/10.2967\/jnumed.123.265871","journal-title":"J Nucl Med"},{"issue":"4","key":"7999_CR61","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1007\/s00330-024-11094-8","volume":"35","author":"R Ebner","year":"2025","unstructured":"Ebner R, Sheikh GT, Brendel M, Ricke J, Cyran CC. ESR Essentials: staging and restaging with FDG-PET\/CT in oncology-practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging. Eur Radiol. 2025;35(4):1894\u2013902. https:\/\/doi.org\/10.1007\/s00330-024-11094-8","journal-title":"Eur Radiol"},{"key":"7999_CR62","doi-asserted-by":"publisher","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group, Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800 . PMID: 25113753; PMCID: PMC4979083. European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer\/Dutch Hemato-Oncology Group; Grupo Espa\u00f1ol de M\u00e9dula \u00d3sea; German High-Grade Lymphoma Study Group; German Hodgkin\u2019sNordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute.","DOI":"10.1200\/JCO.2013.54.8800"},{"issue":"4","key":"7999_CR63","doi-asserted-by":"publisher","first-page":"514","DOI":"10.2967\/jnumed.125.271089","volume":"67","author":"SA Mirshahvalad","year":"2026","unstructured":"MirshahvaladSA, Hodgson D, Kuruvilla J, Veit-Haibach P, Ortega C, Metser U. Prognostic value of interim [18F]FDG PET in Large B-Cell Lymphoma: A systematic review and meta-analysis with a particular focus on interim deauville score 5 disease. J Nucl Med. 2026;67(4):514\u201320. https:\/\/doi.org\/10.2967\/jnumed.125.271089","journal-title":"J Nucl Med"},{"issue":"3","key":"7999_CR64","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/bjh.16875","volume":"192","author":"NG Mikhaeel","year":"2021","unstructured":"Mikhaeel NG, Cunningham D, Counsell N, McMillan A, Radford JA, Ardeshna KM, Lawrie A, Smith P, Clifton-Hadley L, O\u2019Doherty MJ, Barrington SF. FDG-PET\/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study. Br J Haematol. 2021;192(3):504\u201313. https:\/\/doi.org\/10.1111\/bjh.16875","journal-title":"Br J Haematol"},{"issue":"8","key":"7999_CR65","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.2967\/jnumed.120.255034","volume":"62","author":"L Kurch","year":"2021","unstructured":"Kurch L, H\u00fcttmann A, Georgi TW, et al. Interim PET in Diffuse Large B-Cell Lymphoma. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2021;62(8):1068\u201374. https:\/\/doi.org\/10.2967\/jnumed.120.255034.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"issue":"21","key":"7999_CR66","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, Hoos A, Barrington SF, Armand P. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128(21):2489\u201396. https:\/\/doi.org\/10.1182\/blood-2016-05-718528","journal-title":"Blood"},{"issue":"4","key":"7999_CR67","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00259-021-05581-z","volume":"49","author":"YH Li","year":"2022","unstructured":"Li YH, Zhao YM, Jiang YL, Tang S, Chen MT, Xiao ZZ, Fan W, Hu YY, Zhang X. The prognostic value of end-of-treatment FDG-PET\/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUVmax ratio-based evaluation system. Eur J Nucl Med Mol Imaging. 2022;49(4):1311\u201321. https:\/\/doi.org\/10.1007\/s00259-021-05581-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"19","key":"7999_CR68","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.3390\/jcm11195541","volume":"11","author":"C Ferrari","year":"2022","unstructured":"Ferrari C, Pisani AR, Masi T, Santo G, Mammucci P, Rubini D, Sardaro A, Rubini G. Lesion-to-Liver SUVmax ratio to improve the prognostic value of the end of treatment PET\/CT in diffuse large B-Cell lymphoma. J Clin Med. 2022;11(19):5541. https:\/\/doi.org\/10.3390\/jcm11195541","journal-title":"J Clin Med"},{"issue":"1","key":"7999_CR69","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2967\/jnumed.122.264106","volume":"64","author":"F Ricard","year":"2023","unstructured":"Ricard F, Cheson B, Barrington S, Trotman J, Schmid A, Brueggenwerth G, Salles G, Schwartz L, Goldmacher G, Jarecha R, Narang J, Broussais F, Galette P, Liu M, Bajpai S, Perlman E, Gillis J, Smalberg I, Terve P, Zahlmann G, Korn R. Application of the lugano classification for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The PRoLoG consensus initiative (Part 1-Clinical). J Nucl Med. 2023;64(1):102\u20138. https:\/\/doi.org\/10.2967\/jnumed.122.264106","journal-title":"J Nucl Med"},{"issue":"9","key":"7999_CR70","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2967\/jnumed.123.266469","volume":"65","author":"S Ince","year":"2024","unstructured":"Ince S, Laforest R, Itani M, Prasad V, Derenoncourt PR, Crandall JP, Ashrafinia S, Smith AM, Wahl RL, Fraum TJ. Quantitative Assessments of Tumor Activity in a General Oncologic PET\/CT Population: Which Metric Minimizes Tracer Uptake Time Dependence? J Nucl Med. 2024;65(9):1349\u201356. https:\/\/doi.org\/10.2967\/jnumed.123.266469","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"7999_CR71","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.2967\/jnumed.108.057182","volume":"50","author":"R Boellaard","year":"2009","unstructured":"Boellaard R. Standa PE\/CT rds for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50(Suppl 1):S11\u201320. https:\/\/doi.org\/10.2967\/jnumed.108.057182","journal-title":"J Nucl Med"},{"issue":"4","key":"7999_CR72","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2967\/jnumed.116.186353","volume":"58","author":"MA Lodge","year":"2017","unstructured":"Lodge MA. Repeatability of SUV in Oncologic 18F-FDG PET. J Nucl Med. 2017;58(4):523\u201332. https:\/\/doi.org\/10.2967\/jnumed.116.186353","journal-title":"J Nucl Med"},{"key":"7999_CR73","unstructured":"Eertink JJ, Heymans MW, Wiegers SE, Bes AL, Duhrsen U, Huttmann A, Kurch L, Barrington SF, Mikhaeel GN, Lugtenburg PJ, Ceriani L, Zucca E, Gyorke T, Czibor S, Zwezerijnen GJC, Boellaard R, Zijlstra JM, Hanoun C, Zhou. Epub 2025 May 15. PMID: 40371889; PMCID: PMC12485354."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07999-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07999-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07999-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:02:11Z","timestamp":1790971331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07999-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":73,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["7999"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07999-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nothing to disclose.","order":3,"name":"Ethics","label":"Declaration of generative AI use","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LG: Gilead Sciences Lecturer; ADR: advisory and consultant for Roche, Takeda, Incyte, Kite-Gilead, Novartis, Abbvie, Eli-Lilly, Recordati-Rare Disease, SOBI, Astazeneca, J&J, BeOne, BMS; CV: advisory and consultant for AbbVie, BMS, Astra Zeneca, Servier, Incyte, Roche, Pfizer, Novartis, Gentili, Johnson & Johnson, Kite-Gilead, BeOne, Lilly, Kyowa Kirin; PLZ: advisory and consultant for ADC Therapeutics, SOBI, Kite-Gilead, Janssen, Bristol Myers Squibb, AstraZeneca, Roche, Kyowa Kirin, Incyte, BeiGene, Merck Sharp & Dohme, Takeda, Recordati, Novartis. All the other Authors declare non conflict of interest.","order":4,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}